The Parkinson’s Foundation was awarded nearly $800,000 to support research efforts that aim to improve the lives of the…
Articles by Lindsey Shapiro, PhD
Parkinson’s disease patients with inadequately controlled tremors are being sought for a Phase 2 clinical trial of suvecaltamide, an oral…
Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild…
Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for…
A Phase 3 clinical trial of Annovis Bio‘s investigational oral treatment buntanetap in people with early-stage Parkinson’s disease now…
A small group of people with Parkinson’s disease adhered well to an experimental music-based digital therapy to treat gait…
The American Parkinson Disease Association (APDA) will host a free, two-day virtual conference for people with Parkinson’s disease…
High-frequency stimulation of both the brain’s primary motor cortex (M1) and its dorsolateral prefrontal cortex (DLPFC) — two regions with…
Researchers have developed a video-based algorithm to predict the severity of tremor in Parkinson’s disease patients based on…
Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people…